We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Orders Clinical Hold on Five Trials of Gilead’s Checkpoint Inhibitor Magrolimab
FDA Orders Clinical Hold on Five Trials of Gilead’s Checkpoint Inhibitor Magrolimab
The FDA has placed a clinical hold that affects five trials of Gilead Sciences’ investigational blood cancer drug, which it just acquired two years ago.